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Abstract: Human chromosomal fragile sites are specific genomic regions which exhibit gaps or breaks on metaphase 
chromosomes following conditions of partial replication stress. Fragile sites often coincide with genes that are frequently 
rearranged or deleted in human cancers, with over half of cancer-specific translocations containing breakpoints within 
fragile sites. But until recently, little direct evidence existed linking fragile site breakage to the formation of cancer-
causing chromosomal aberrations. Studies have revealed that DNA breakage at fragile sites can induce formation of 
RET/PTC rearrangements, and deletions within the FHIT gene, resembling those observed in human tumors. These find-
ings demonstrate the important role of fragile sites in cancer development, suggesting that a better understanding of the 
molecular basis of fragile site instability is crucial to insights in carcinogenesis. It is hypothesized that under conditions of 
replication stress, stable secondary structures form at fragile sites and stall replication fork progress, ultimately resulting 
in DNA breaks. A recent study examining an FRA16B fragment confirmed the formation of secondary structure and DNA 
polymerase stalling within this sequence in vitro, as well as reduced replication efficiency and increased instability in hu-
man cells. Polymerase stalling during synthesis of FRA16D has also been demonstrated. The ATR DNA damage check-
point pathway plays a critical role in maintaining stability at fragile sites. Recent findings have confirmed binding of the 
ATR protein to three regions of FRA3B under conditions of mild replication stress. This review will discuss recent ad-
vances made in understanding the role and mechanism of fragile sites in cancer development. 
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INTRODUCTION 
  Genomic instability is a common cause of chromosomal 
aberrations in many types of tumor cells. Cells can acquire 
DNA damage through various extrinsic or intrinsic factors. 
DNA damage commonly arises following exposure to ex-
ogenous factors such as UV radiation, ionizing radiation, 
chemotherapy, and endogenous factors such as reactive oxy-
gen species [1]. Chromosomal fragile sites, which are espe-
cially susceptible to DNA breakage, have also been sug-
gested as contributory to the formation of cancer-specific 
chromosomal aberrations [2].  
  Chromosomal fragile sites are defined as regions of the 
genome which exhibit gaps or breaks on metaphase chromo-
somes under conditions of partial replication stress [3]. 
Many genes identified as tumor suppressors or oncogenes 
are located at or within fragile sites [4]. The deletion of tu-
mor suppressors and the amplification of oncogenes are fre-
quently consequences of breakage at these sites. Studies 
have also demonstrated a significant association between 
sites of breakage in cancer-specific chromosomal rearrange-
ments and the location of fragile sites [5-7]. Several onco-
genic viruses target and preferentially integrate at these   
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chromosomal regions [4]. Based on this information, it has 
been proposed that fragile sites may directly contribute to 
cancer development, although their direct role remains un-
clear. In a recent study by Gandhi et al., DNA breakage at 
fragile sites directly contributed to the formation of a cancer-
specific chromosomal translocation found in human papil-
lary thyroid carcinoma [8].  
  Fragile sites are divided into two major classes, based on 
their frequency in the population, and are further divided 
according to their mode of induction in cultured cells. Com-
mon fragile sites have been observed in all individuals and 
are therefore believed to represent a normal component of 
chromosome architecture [9]. Most common fragile sites are 
induced by low doses of aphidicolin (APH), an inhibitor of 
DNA polymerases ,  and  [10, 11]. Other common fragile 
sites can occur following treatment with bromodeoxyuridine 
(BrdU) or 5-azacytidine (5-aza). In contrast, rare fragile sites 
are found in less than 5% of the population and are inherited 
in a Mendelian manner [12, 13]. Most of these sites are ex-
pressed under folate-deficient conditions, whereas others are 
induced by chemicals that bind AT-rich DNA, such as dis-
tamycin-A or berenil. Recently, Mrasek et al. found that 
APH can induce all types of common and rare fragile sites, 
suggesting that their expression is less dependent on their 
currently defined mode of induction, and instead, a classifi-
cation of fragile sites based on their frequency is more ap-
propriate [14]. In addition, various dietary and environ-
mental factors can significantly increase fragile site break-Fragile Site Instability in Cancer  Current Genomics, 2010, Vol. 11, No. 5    327 
age, including caffeine, ethanol, pesticides, and cigarette 
smoke [3]. 
  While the molecular basis remains elusive, several fac-
tors may contribute to fragile site breakage. Although a con-
sensus sequence has not yet been identified among all fragile 
sites, all common fragile DNAs examined to date are com-
prised of AT-rich flexibility islands, with the potential of 
forming secondary structures that are much more stable than 
other genomic regions [15, 16]. These regions can extend 
over megabases of DNA, with gaps or breaks occurring 
throughout [17]. Fragility at rare sites is attributed to the 
expansion of either a CGG repeat or an AT-rich minisatel-
lite, which can also form stable secondary structures. All 
fragile sites studied so far are late-replicating regions of the 
genome, and their replication can be further delayed in the 
presence of induction agents, with some fragile site alleles 
remaining unreplicated in late G2 [18-22]. In addition, the 
ATR (Ataxia-telangiectasia and Rad3 Related)-dependent 
DNA damage checkpoint pathway is crucial for fragile site 
maintenance, since a deficiency of proteins including ATR 
[23, 24] and its downstream targets, such as BRCA1 [25] 
and CHK1 [26], result in a dramatic increase in fragile site 
breakage. Therefore, it is hypothesized that at fragile sites, 
under conditions of replication stress, the replicative polym-
erases may uncouple from the helicase, resulting in long re-
gions of single-stranded DNA and thus promoting the forma-
tion of stable secondary structures. Consequently, these 
structures may stall replication fork progression, triggering 
an ATR pathway response. Defective ATR pathway signal-
ing could result in DNA breakage at these sites, and thus 
lead to cancer-specific chromosomal aberrations [6]. 
  Here, we will review recent advances made in under-
standing the role and mechanism of fragile sites in cancer 
development. We will discuss the importance of fragile sites, 
direct evidence of their involvement in cancer, sequence 
characteristics of fragile sites that contribute to their instabil-
ity, and the role of the ATR-dependent DNA damage check-
point pathway in their breakage. 
IMPORTANCE OF FRAGILE SITES IN CANCER 
  Fragile sites are normally stable in cultured cells. How-
ever, these regions are highly susceptible to chromosomal 
deletions, rearrangements, and sister chromatid exchanges 
following their induction with replication inhibitors [27, 28]. 
Most rare fragile sites can be induced by removal of folic 
acid or treatment with fluorodeoxyuridine (FUdR), an inhibi-
tor of folate metabolism. Other rare sites are expressed upon 
treatment with minor groove binders, such as distamycin-A 
or berenil, as well as BrdU, a nucleoside analog of thymidine 
that is incorporated into newly synthesized DNA. BrdU is 
also an inducer of several common fragile sites, along with 
5-aza, whereas most sites are induced by APH, an inhibitor 
of DNA polymerases ,  and . Common fragile sites can 
also be induced by various environmental agents and chemi-
cals, including caffeine, ethanol, and cigarette smoke   
(Table 1). 
Table 1.  Environmental, Dietary and Medicinal Inducers/Enhancers of Fragile Sites 
Chemical/Condition Uses  References 
5-azacytidine  chemotherapeutic agent   [40] 
actinomycin D  chemotherapeutic agent  [40] 
atenolol hypertension  drug  [41] 
benzene  found in cigarette smoke, gasoline fumes  [40] 
bleomycin chemotherapeutic  agent  [40] 
busulfan chemotherapeutic  agent  [40] 
caffeine  dietary agent  [5, 29] 
carbon tetrachloride  found in refrigerants, pesticides  [40] 
chlorambucil chemotherapeutic  agent  [40] 
cigarette smoke  dietary and environmental agent  [33, 34] 
cytosine arabinoside  chemotherapeutic agent  [40] 
diethylnitrosamine  found in cigarette smoke, pesticides, cured meat, whiskey  [40] 
dimethyl sulfate  found in dyes, drugs, perfumes, pesticides  [40] 
ethanol  dietary agent  [30, 31] 
FUdR chemotherapeutic  agent  [40] 
hypoxia  low oxygen; found in tumor microenvironment  [32] 
methotrexate chemotherapeutic  agent  [40] 
pesticides  environmental agent  [35, 36, 39] 328    Current Genomics, 2010, Vol. 11, No. 5  Dillon et al. 
  Caffeine, an inhibitor of phosphoinositide 3-kinase re-
lated kinases, including ATR and ATM (Ataxia-
telangiectasia mutated), significantly increases common 
fragile site breakage in conjunction with FUdR and APH [5, 
29]. Ethanol and APH also significantly increases fragile site 
breakage [30]. Interestingly, cells from chronic alcohol users 
show a significantly higher frequency of fragile site and 
chromosomal breakage compared to control individuals, 
suggesting long term alcohol use alone can induce fragile 
site expression [31]. Hypoxic conditions induced fragile site 
breakage in GMA32 Chinese hamster cells, with or without 
the addition of other fragile site-inducing chemicals [32]. 
Kao-Shan  et al. found that peripheral blood lymphocytes 
from cigarette smokers show significantly greater fragile site 
breakage compared to non-smokers [33]. Stein et al. found 
that treatment of peripheral blood lymphocytes with low-
doses of APH results in increased fragile site breakage in 
active smokers compared to non-smokers and patients with 
small cell lung cancer who stopped smoking [34]. These 
results suggest that active exposure to cigarette smoke in-
creases the potential of breakage at fragile sites, and that this 
risk is reversible.  
  Exposure to pesticides also results in an increased sus-
ceptibility to fragile site breakage. Blood lymphocytes from 
pesticide sprayers and flower collectors working in green-
houses show greater fragile site breakage than normal indi-
viduals following treatment with APH, with these results 
being reproducible a year later [35, 36]. An association be-
tween pesticide exposure and an increased risk of hema-
topoietic tumors has been observed [37, 38]. The APH-
induced damage was enhanced at fragile sites containing 
breakpoints involved in leukemias and non-Hodgkin’s lym-
phoma, supporting a role for pesticide-associated fragile site 
breakage in development of these cancers. Like cigarette 
smoke exposure, the effect of pesticide exposure on fragile 
site breakage is also transient. APH-induced fragile site 
breakage in blood cells from farmers increased significantly 
post-exposure to organophosphate-based pesticides com-
pared to pre-exposure samples, where the farmers had not 
been exposed to pesticides for at least one month [39].  
  Several mutagens and carcinogens can also induce fragile 
site breakage. Yunis et al. screened various mutagens for 
their ability to induce fragile site breakage [40]. The 
mutagens found to induce breakage were diverse and in-
cluded benzene, a component found in cigarette smoke and 
gasoline fumes; carbon tetrachloride, formerly widely used 
in refrigerants and pesticides; diethylnitrosamine, found in 
cigarette smoke, pesticides, cured meat, and whiskey; and 
dimethyl sulfate, used in the manufacturing of dyes, drugs, 
perfumes, and pesticides. Several chemotherapeutic agents 
were also identified, including actinomycin D, bleomycin, 
busulfan, chlorambucil, cytosine arabinoside, 5-aza, FUdR, 
and methotrexate. The action of these mutagens was en-
hanced 3- to 8-fold with the addition of caffeine. 
  Peripheral blood lymphocytes from hypertensive patients 
taking atenolol, a common -blocker, have more frequent 
chromatid and chromosome breaks than normal individuals, 
and these breaks are preferentially located at fragile sites 
[41]. While antihypertensive drugs have been examined for 
genotoxicity and carcinogenicity, a recent review suggests 
that studies to date may lack sufficient evidence to evaluate 
the potential risks of these drugs in humans [42]. One geno-
toxicity study of atenolol revealed a statistically significant 
increase in the number of micronuclei in patents taking at-
enolol compared to control [43]. Combined, these data sug-
gest that more long-term research needs to be performed to 
assess the risk of these drugs on carcinogenesis, and that 
fragile site breakage may be involved in the carcinogenesis 
process. 
  Variability of fragile site breakage has been observed 
within individuals [44]. This phenomenon may reflect expo-
sure to such mutagens/carcinogens, with high levels being 
associated with cancer patients [45]. Tumor cells also dem-
onstrate an association between sites of breakage in recurrent 
chromosome abnormalities and the position of fragile sites. 
The two most highly breakable fragile sites, FRA3B and 
FRA16D, lie within the tumor suppressor genes FHIT and 
WWOX, respectively. The FHIT gene is often involved in 
deletions which map specifically to the fragile site region in 
various types of cancer [46-51], and deletion of WWOX is 
also frequently observed in tumor cells [52-57]. It has been 
proposed that fragile sites may also play a role in the break-
age-fusion-bridge model of gene amplification [58, 59], 
since proto-oncogenes such as MYC [60] and MET [61] are 
located at fragile sites FRA8C and FRA7G, respectively. In 
addition to environmental mutagens, several oncogenic vi-
ruses including human papilloma virus [62], Hepatitis B 
[63], and Epstein-Barr [64], have been shown to target and 
preferentially integrate at fragile sites.  
  While strong correlations exist between fragile site loca-
tions and sites of breakage in other chromosome rearrange-
ments, such as translocations, until recently there was no 
systematic demonstration of the location of fragile sites rela-
tive to all reported translocations in tumor cells. After the 
examination of all known cancer-specific recurrent translo-
cations, it was determined that over half (52%) of transloca-
tion breakpoints in participating gene sets correspond to 
fragile site positions [65]. Furthermore, 65% of the break-
points were located within common fragile sites, as opposed 
to rare sites, and most cancers associated with the transloca-
tions examined had little or no genetic component. These 
results suggest that exposure to fragile site-inducing chemi-
cals may confer a risk for the formation of cancer-specific 
rearrangements. This study focused on simple translocations 
involving two genes, or deletions which lead to fusion tran-
scripts, and excluded single gene deletions (the most com-
mon aberrations associated with fragile sites) and chromo-
somal insertions or more complex translocations involving 
multiple genes. Therefore, the association between transloca-
tion breakpoints and fragile site locations revealed in this 
study is likely to be an underestimation. 
  Because the evidence strongly supports a link between 
fragile sites and cancer development, it is essential to inves-
tigate the mechanism of fragile site breakage, and to examine 
the consequences of breakage at these sites in order to dem-
onstrate a causative role in tumorigenesis. Also, it will be 
important to identify factors that contribute to chromosomal 
fragility, such as DNA sequence, proteins and environ-
mental/dietary agents, since fragile sites can be induced by a 
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DIRECT EVIDENCE OF FRAGILE SITE INVOLVE-
MENT IN CANCER DEVELOPMENT 
  Despite a long-established connection between fragile 
sites and the formation of cancer-specific chromosomal aber-
rations in many different studies [66], no studies have dem-
onstrated direct evidence of fragile site breakage leading to 
cancer-causing chromosomal aberrations. Most experiments 
testing fragile site induction through exposure to chemicals 
examined DNA breakage on the cytogenetic level. However, 
two recent studies examining fragile site breakage at the nu-
cleotide level, have revealed that DNA breakage at fragile 
sites can lead to the formation of RET/PTC rearrangements 
[8], as well as deletions within the FHIT gene [67], resem-
bling those observed in human tumors. 
  FRA3B, the most frequently expressed fragile site in the 
genome, is located within the tumor supressor gene FHIT 
[68]. Deletions within FHIT have been associated with vari-
ous human cancers including breast, lung, cervical, and eso-
phageal [66]. Durkin et al. observed submicroscopic dele-
tions within FHIT/FRA3B following treatment of human-
mouse chromosome 3 somatic hybrid cells with low doses of 
APH [67]. The APH-induced deletions spanned ~200-600 
Kb within FHIT and were centered on exon 5, within the 
breakpoint cluster of FRA3B. The location and size of APH-
induced FHIT deletions were consistent with those observed 
in esophageal cancer cell lines, small-cell and non-small cell 
lung carcinomas, and breast cancers. Sequence analysis of 
the APH-induced deletion breakpoints showed no sequence 
homology, suggesting nonhomologous end-joining (NHEJ)-
mediated repair. Interestingly, chromosomes from clones 
containing APH-induced FRA3B deletions exhibited a sig-
nificant decrease in FRA3B breakage following additional 
APH treatment. While these studies show directly that frag-
ile site breakage can lead to mutations like those seen in hu-
man tumors, these experiments were carried out in mouse 
hybrid cells, which may not respond similarly to human 
cells. 
  Genes participating in the two major types of RET/PTC 
rearrangements,  RET/PTC1 and RET/PTC3, are all located 
within known common fragile sites [65]. RET/PTC rear-
rangements, a common cause of papillary thyroid carcinoma, 
result in the fusion of the RET tyrosine kinase domain to the 
5’ portion of various constitutively expressed genes [69]. 
RET  (rearranged during transfection) encodes for a cell 
membrane receptor tyrosine kinase protein whose ligands 
belong to the glial cell line-neurotropic factor (GDNF) fam-
ily [70].  In the thyroid gland, RET is highly expressed in 
neural crest derived C-cells but not in follicular cells, where 
it can be activated through the formation of RET/PTC rear-
rangements [69]. In RET/PTC1, RET is rearranged with 
CCDC6, while in RET/PTC3 is rearranged with NCOA4 
[71]. Both CCDC6 and NCOA4 are located closer than ex-
pected to RET in interphase nuclei of normal human thyroid 
cells, potentiating rearrangement formation [72, 73]. RET 
and NCOA4 are both located within the APH-induced com-
mon fragile site FRA10G, and CCDC6 is located within the 
BrdU-induced common fragile site FRA10C. Recently, Gan-
dhi et al. found that exposure of human thyroid epithelial 
cells to the fragile site-inducing chemicals APH, BrdU, and 
2-AP results in the formation of RET/PTC1 rearrangements 
like those observed in patients [8]. DNA breakage was ob-
served within RET, CCDC6, and to a lesser extent NCOA4 
using fluorescence in situ hybridization, following exposure 
to fragile site-inducing chemicals, consistent with the mode 
of induction for the fragile site where each gene is located.  
  APH-induced DNA breakage within RET was identified 
to be located within intron 11 [8], the major breakpoint clus-
ter region within patients [74]. Interestingly, these break-
points were located within 2-15 basepairs of breakpoints 
identified from human papillary thyroid carcinomas contain-
ing  RET/PTC rearrangements. The breakpoints isolated in 
patient samples were identified post-rearrangement, while 
the breakpoints induced by APH were identified pre-
rearrangement. In most patient tumors, small insertions or 
deletions ranging from 1-18 nucleotides surround the fusion 
points, suggesting a possible break repair mechanism after 
the initial breaks that form the rearrangement. Schwartz et al. 
found that downregulation of Rad51, DNA-PKcs, and Ligase 
IV, key components of the homologous recombination (HR) 
and NHEJ repair pathways, significantly increases fragile 
site breakage with APH treatment, and that H2AX and 
phosphorylated DNA-PKcs foci were located at expressed 
fragile sites [75]. Together, these data suggest a role for both 
the HR and NHEJ repair pathways in the repair of fragile site 
breakage. However, more research is needed to elucidate the 
contribution of these pathways in the formation of RET/PTC 
rearrangements as a result of fragile site breakage. 
 RET/PTC rearrangements are commonly associated with 
radiation exposure, especially in children. However, most 
adult tumors containing RET/PTC rearrangements are spo-
radic and patients lack a history of radiation exposure [76]. 
Most importantly, the observation that fragile site-inducing 
chemicals can cause the formation of RET/PTC1 rearrange-
ments, and significant breakage at RET and CCDC6 but not 
NCOA4 [8], suggests a role for fragile sites in the formation 
of sporadic RET/PTC1 tumors. Interestingly, an increasing 
prevalence of RET/PTC1 over RET/PTC3 rearrangements 
has been observed in sporadic papillary thyroid carcinomas 
[77], which is consistent with the experimental data and fur-
ther supports fragile site involvement in sporadic papillary 
thyroid carcinomas. Overall, these experiments show direct 
involvement of fragile sites in the formation of cancer-
causing chromosomal translocations within human cells. 
  According to the National Cancer Institute, thyroid can-
cer is now the fastest growing cancer among both men and 
women, increasing at a rate of 6.5 percent a year from 1997-
2006 [78]. Of all types of thyroid cancer, papillary thyroid 
carcinoma is the only subtype in which the rate of incidence 
increased consistently regardless of race or ethnicity [79]. 
Interestingly, in a study examining cancer incidence in U.S. 
Air Force active duty personnel between 1989-2002, thyroid 
cancer was the third most frequent invasive cancer in women 
and the fifth most frequent in men [80]. Compared to the 
U.S. general population, thyroid cancer in women was over 
four times more prevalent in the U.S. Air Force. More im-
portantly, overall cancer incidence in the U.S. Air Force 
were significantly reduced compared to the general popula-
tion, suggesting that the increase in thyroid cancer may 
partly be the result of occupational exposure. Several com-
ponents of unique occupational conditions for active duty 330    Current Genomics, 2010, Vol. 11, No. 5  Dillon et al. 
Air Force personnel, including jet fuel, napalm, and high 
altitudes, have been shown to induce fragile site breakage. 
While the cause of the increased thyroid cancer incidence is 
unknown, exposure to various environmental and dietary 
fragile site-inducing chemicals and conditions is a potential 
causal factor. 
DNA SECONDARY STRUCTURE AND REPLICA-
TION FORK STALLING AT FRAGILE SITES 
  Understanding the molecular basis of fragile site break-
age is critical for dissecting the role of fragile sites in cancer. 
Several intrinsic factors may contribute to their expression. 
Replication timing experiments have demonstrated that all 
fragile sites examined so far, including FRA1H [22], FRA2G 
[22], FRA3B [19], FRA7H [20], FRA10B [21], FRA16B 
[21], and FRAXA [18] exhibit late replication, which can be 
further delayed by the addition of replication inhibitors, with 
some fragile site alleles remaining unreplicated in the late G2 
phase [19, 20]. Although there is no consensus sequence 
among fragile sites, most fragile DNAs studied to date can 
form highly stable secondary structures [15, 16]. Evidence 
for secondary structure formation at fragile sites has largely 
been generated by the Mfold program [81], which predicts 
secondary structure formation of a single-stranded DNA. 
The first evidence of fragile DNA forming a secondary 
structure in vitro came from the ability of the CGG repeat, 
which underlies the basis of fragility at rare, folate-sensitive 
fragile sites, to form both quadruplex [82] and hairpin struc-
tures [83]. Furthermore, the formation of such structures by 
the CGG repeat presents a significant block to replication 
both in vitro [84] and in vivo [85]. Additionally, a polymor-
phic AT-rich sequence within the common fragile site 
FRA16D is predicted to form a cruciform that can block rep-
lication and increase chromosomal instability in yeast [86]. 
A recent study examining the rare fragile site FRA16B dem-
onstrated the ability of an AT-rich site, which comprises the 
majority of fragile sites, to form a secondary structure in 
vitro [87]. 
  Several studies have demonstrated a significant effect of 
cis-acting factors, including replication orientation and dis-
tance relative to the origin on the instability of fragile site 
DNA sequences. This effect may be due to the ability of an 
unstable DNA to form a stable secondary structure, and/or 
location of an alternative DNA structure within a region that 
maintains single-strandedness during replication, such as the 
Okazaki initiation zone (OIZ), which could promote the 
formation of such structures. Reports examining replication 
of expanded trinucleotide repeats in mammalian cells, such 
as CTG [88], GAA [89], and CGG [90], indicate that when 
the more structure-prone strand serves as the lagging strand 
template (a situation dictated by replication orientation), mu-
tation events increase. The types of mutations (i.e. insertions 
and deletions) also differed based on the orientation of the 
DNA. When both strands can form an alternative structure 
(as with FRA16B), a similar orientation effect is also seen, 
likely due to the difference in the structures, as evidenced by 
the different electrophoretic mobilities produced by the two 
strands in native polyacrylamide gels [87]. The mutation rate 
for the clone in which the more stable structure served as the 
lagging strand template was statistically significant higher 
than that of the clone in opposite orientation [87]. These 
studies also revealed a significant effect on the distance from 
the repeat to the replication origin. Placing a repetitive frag-
ment of DNA close to the origin of replication would cause 
the unstable sequence to occupy the first OIZ, potentially 
out-competing the binding of RPA protein. Repeats located 
further away from the origin would occupy different OIZs, 
and could be trumped by the initial binding of RPA in the 
first OIZ, which would propagate into the second, third, and 
so on [87]. In addition to mutation rate, replication orienta-
tion and distance relative to the origin also significantly af-
fect replication efficiency of CGG and FRA16B-containing 
constructs. Edamura et al. found that constructs with ex-
panded CGG repeats located further from the origin of repli-
cation replicated less efficiently compared to constructs with 
the same orientation located closer to the origin; plasmids in 
which CGG repeats served as the lagging strand template 
demonstrated a higher replication rate relative to plasmids in 
which CCG repeats served as the lagging strand template 
[90]. In a study of FRA16B replication in human cells, Bur-
row et al. found that various FRA16B-containing constructs 
replicated less efficiently compared to a control without frag-
ile DNA, and that both orientation and distance from the 
origin significantly affected its replication rate [87]. 
  A decrease in replication rate by a stalled fork could be 
responsible for the late replication observed at fragile sites. 
To date, synthesis of fragile site DNA has been investigated 
using primer extension assays both in vitro and in human 
cell-free extracts, and analyzing synthesis intermediates iso-
lated for 2D gel electrophoresis in yeast. Examination of 
replication intermediates from cells containing AT-rich se-
quences within common fragile site FRA16D in S. cerevisiae 
showed site-specific replication fork stalling, depending on 
the length of the AT repeat [86]. Furthermore, correlation 
with secondary structure predictions suggests that the struc-
ture formed by this repeat is responsible for the fork stalling. 
Using an in vitro primer extension assay, synthesis of the 
same fragile site by human replicative polymerases  and  
confirmed polymerase stalling at sites predicted to form in-
hibitory DNA structures, which was alleviated by the addi-
tion of WRN protein [91]. The same study examined primer 
extension using HeLa cell-free extracts, and obtained similar 
results. Interestingly, FRA16D regions with increased DNA 
flexibility and accompanying high A/T content were not suf-
ficient to inhibit DNA synthesis, but sequences with the pro-
pensity to form secondary structures were significantly more 
inhibitory to replication. Fragile site FRA16B exhibits char-
acteristics of both common and rare sites, and showed strong 
polymerase pause sites specifically within the fragile DNA 
sequence in vitro, likely due to its ability to form an alterna-
tive DNA structure [87]. 
  These data strongly suggest that the secondary-structure 
forming ability of fragile site DNAs greatly contributes to 
their instability by inhibiting replication. Even without repli-
cation stress, fragile sites show replication blockage during 
synthesis. While fragile site instability primarily arises from 
DNA polymerase stalling, visualization of FRA16B replica-
tion fork constructs by electron microscopy showed a high 
propensity for stalled forks to spontaneously regress during 
synthesis, a previously unidentified mechanism of instability 
at these sites [87]. In addition, measurements of the non-
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were much shorter than predicted, consistent with the dele-
tion mutants produced from replication of FRA16B in 
HEK293T cells. These results suggest yet another mecha-
nism of fragile site instability in which polymerase bypass 
may occur at regions of secondary structure formation. 
Based on these results, fragile DNAs likely contain intrinsic 
features that make them difficult to replicate, and in the pres-
ence of replication stress, which can be produced by the ad-
dition of chemicals such as aphidicolin, replication is further 
delayed. The addition of aphidicolin or other fragile site-
inducing chemicals will likely create an accumulation of 
long, single-stranded DNA regions caused by the functional 
uncoupling of replicative DNA polymerase and helicase ac-
tivities. These regions are then highly prone to forming sta-
ble secondary structures which could further stall progres-
sion of the replication fork, triggering activation of ATR and 
its downstream products. A small fraction of fragile sites 
escapes the replication checkpoint, which would lead to 
breakage at fragile sites. 
REGULATION OF COMMON FRAGILE SITE STA-
BILITY BY THE ATR PATHWAY 
  ATR kinase is a DNA damage sensor protein that has a 
major role in regulating stability at common fragile sites. 
ATR works with downstream target proteins to respond to 
stalled and collapsed replication forks, resulting in a block in 
further replication and mitosis progression and the promo-
tion of DNA repair, recombination, or apoptosis [92, 93]. 
The loss of functional ATR in cells results in a defective 
DNA damage response to agents which block replication 
fork progression, including APH and hydroxyurea [94-96], 
and conditions of hypoxia [97]. Casper et al. found that cells 
deficient in ATR, but not ATM, display up to a 20-fold in-
crease in fragile site breakage following treatment with low 
doses of APH compared to control cells [23]. Also, a defi-
ciency in ATR alone is enough to induce fragile site break-
age in cells without treatment with replication inhibitors. 
Cells from patients with Seckel syndrome, who express low 
levels of ATR protein due to a hypomorphic mutation in the 
ATR gene, exhibit an increase in chromosomal breakage at 
common fragile sites compared to unaffected individuals 
[24]. Furthermore, mice hypomorphic for ATR also display 
an increase in common fragile site breakage and a significant 
delay in checkpoint induction [98]. While the loss of ATM 
alone does not cause increased common fragile site breakage 
[23], it is involved in maintaining fragile site stability in the 
absence of ATR. Ozeri-Galai et al. found that a loss of both 
ATR and ATM significantly increases APH-induced com-
mon fragile site breakage compared to the loss of ATR 
alone. Also, ATM is activated and forms nuclear foci with 
H2AX following treatment with low doses of APH [99]. 
These findings indicate that ATR is the major pathway re-
sponsible for maintaining fragile site stability, but that ATM 
also plays a secondary role, perhaps through a downstream 
response to double strand breaks that form as a result of 
ATR deficiency. 
  Other downstream targets of the ATR-mediated pathway 
involved in maintaining fragile site stability include BRCA1 
[25], CHK1 [26], SMC1 [100], FANCD2 [101], HUS1 
[102], WRN [103], and Claspin [104] (Table 2). BRCA1 is a 
primary target of both ATR and ATM phosphorylation in 
response to DNA damage. Cells lacking BRCA1 show sig-
nificantly more fragile site breakage after treatment with 
APH compared to control cells [25]. Also, cells expressing 
mutant BRCA1 exhibit elevated levels of fragile site break-
age but lack the G2/M checkpoint, suggesting BRCA1 regu-
lates fragile site stability through its role at this checkpoint. 
  CHK1 kinase is the major downstream target of ATR and 
serves as the central regulator of the ATR checkpoint path-
way. Loss of CHK1, but not the ATM regulated CHK2, in 
cells was found to result in a significant increase in fragile 
site breakage after treatment with APH [26]. Also, it was 
found that both ATR and ATM phosphorylate CHK1 follow-
ing treatment with low doses of APH [99]. These data sug-
gest that the role of ATM in fragile site maintenance may be 
to activate the ATR pathway through phosphorylation of 
CHK1, when ATR is missing or fails to properly respond to 
damage. HUS1 is a member of the PCNA-related 9-1-1 
Table 2.  DNA Damage Checkpoint Proteins Shown to Regulate Common Fragile Site Stability 
Protein Function  Reference 
ATM  Kinase, maintains fragile site stability in the absense of ATR  [99] 
ATR 




Phosphorylated by ATR, major downstream target of ATR, necessary for G2/M checkpoint activation following replica-
tion stress 
[25] 
CHK1  Kinase, phosphorylated by ATR in response to replication stress, central regulator of ATR pathway  [26] 
Claspin  Phosphorylated and interacts with CHK1 in response to replication stress  [104] 
FANCD2 
Fanconi Anemia pathway protein, phosphorylated by ATR leading to activation by mono-Ub, activated by replication 
stress 
[101] 
HUS1  Member of the 9-1-1 complex, promotes phosphorylation of ATR substrates  [102] 
SMC1  Chromosomal structural maintenance protein, member of the cohesion complex  [100] 
WRN  ATP-dependent 3’-5’ helicase, 3’-5’ exonuclease  [91, 103] 332    Current Genomics, 2010, Vol. 11, No. 5  Dillon et al. 
complex which promotes the phosphorylation of ATR sub-
strates like CHK1 and helps aid in DNA repair through asso-
ciation with multiple factors. A significant increase in DNA 
breakage at common fragile sites was observed after inacti-
vation of HUS1 [102]. SMC1 is a chromosomal structural 
maintenance protein that belongs to the cohesin complex, 
which is necessary for sister chromatid cohesion and DNA 
repair and acts to hold DNA strands in place. After treatment 
with APH, cells exhibit an ATR-dependent, ATM-
independent, phosphorylation of SMC1 and increased fragile 
site breakage after SMC1 inhibition [100]. Claspin is another 
member of the ATR pathway that is required for ATR-
mediated phosphorylation of CHK1 in response to replica-
tion stress. Inhibition of claspin expression increases fragile 
site expression, with or without APH treatment [104]. 
  Several studies have focused on the Fanconi anemia 
pathway, which responds to DNA cross-linking damage and 
chromosomal instability through a yet unknown mechanism 
involving interactions with BRCA1 and RAD51 and re-
cruitment of BRCA2, in regulation of fragile site stability 
[101]. Fanconi anemia is an autosomal recessive disease 
associated with an increase in cancer susceptibility, and is 
most often a result of mutations in FA genes (subtypes A, B, 
C, D1, D2, E, F, G, I, J, L, M, N) [105]. Chromosomal 
breaks in blood lymphocytes of FA patients are preferen-
tially located at fragile sites [106], and FANCD2 and FANCI 
specifically associate with common fragile site loci under 
conditions of replication stress [107]. Also, ATR phosphory-
lates the FA protein, FANCD2, and is required for its mono-
ubiquitination [108], which is necessary for its activation 
during S-phase and subsequent colocalization with BRCA1 
and RAD51[109], in response to replication stress. Treat-
ment of both FANCD2 knockdown cells and FA-patient 
cells with APH results in increased fragile site breakage 
[101]. Interestingly, cigarette smoke, a known induction 
agent of fragile site expression, suppresses FANCD2 expres-
sion in airway epithelial cells [110]. It will be intriguing to 
investigate the connection between the cancer susceptibility 
of FA patients and fragile site-mediated cancer-causing rear-
rangements. 
  WRN is an ATP-dependent 3’-5’ helicase and 3’-5’ ex-
onuclease that is targeted by ATR and interacts with ATR-
pathway proteins. Increased fragile site breakage is seen in 
cells of patients with Werner syndrome (a premature aging 
disease associated with a greater susceptibility to cancer de-
velopment), and in WRN knockdown cells after treatment 
with APH [103]. In addition, double knockdown of WRN 
and ATR did not result in increased chromosomal damage 
compared to WRN or ATR knockdown alone, suggesting 
these proteins work in a common pathway. The activity of 
WRN in fragile site maintenance still remains unclear. Pirzio 
et al. presented data suggesting that WRN helicase, not ex-
onuclease activity, plays the main role in stabilizing fragile 
sites [103]. In contrast, Shah et al. found that neither WRN 
helicase or exonuclease activity was necessary for polym-
erase  progression past stalled replication forks within vari-
ous FRA16D sequences in vitro [106]. 
  While the importance of the ATR pathway in fragile site 
maintenance has been established, the mechanism is not 
fully understood. Recently, Wan et al. found that ATR binds 
(directly or through complexes) to fragile site FRA3B pref-
erentially compared to non-fragile regions under conditions 
of mild replication stress [111]. This binding increases in a 
dose-dependent manner, peaking at 0.4μM APH, and de-
creases at higher APH concentrations. While the level of 
ATR binding to FRA3B changes with treatment, the cellular 
levels of ATR, phospho-ATR (Ser 428), and ATR interact-
ing proteins ATRIP and TopBP1 remain unchanged. This 
suggests that ATR binding to the fragile site is guided ini-
tially by the level of replication stress signals generated at 
FRA3B due to APH treatment, and then sequestered from 
FRA3B regions by successive signals from other non-fragile 
site regions, which are produced at the higher concentrations 
of APH. Furthermore, the kinase activity of ATR was re-
quired for ATR binding to FRA3B in response to APH 
treatment. While ATR kinase activity is known to be neces-
sary for phosphorylation of downstream targets to activate 
the checkpoint signaling cascade [93], these data indicate 
that the kinase activity of ATR is also necessary for ATR 
interaction to fragile site regions, most likely through phos-
phorylation of ATRIP and TopBP1 to stabilize the interac-
tion between these three proteins and the fragile DNA. Two 
models which are not mutually exclusive have been pro-
posed to explain how ATR helps to maintain fragile site sta-
bility [112]. The first model states that a loss of ATR can 
lead to a bypass of stalled replication forks at fragile sites, 
ultimately resulting in a failure of checkpoint pathways to 
prevent entry into mitosis, thus leaving DNA breakage at the 
unreplicated DNA. The second model states that a loss of 
ATR leads to replication fork collapse at fragile sites and 
improper resolution of these structures by ATR leads to 
DNA breaks. The current information about the involvement 
of ATR at fragile sites supports a combination of both mod-
els. The preferential binding of ATR protein to FRA3B frag-
ile DNAs following APH treatment [111] suggests that ATR 
plays a possible local role in stabilizing stalled replication 
forks at fragile regions. Also, this binding and increased 
fragile site breakage following the inhibition of various 
members of the ATR pathway suggest that ATR response to 
fragile sites under conditions of replication stress can acti-
vate the ATR-dependent pathway. Finally, decreased ATR 
binding to FRA3B at higher concentrations of APH [111], 
which induce more chromosomal gaps or genomic breaks, 
supports the idea that DNA breakage at fragile sites is due to 
a failure of ATR to stabilize replication forks and to signal a 
checkpoint response. 
  ATR and many downstream proteins (e.g. ATM, 
BRCA1, CHK1, HUS1, SMC1, FANCD2, WRN, and 
claspin) are important in maintaining fragile site stability. 
However, in response to replication stress, whether these 
proteins act in the ATR pathway and their specific role as 
adaptor, transducer or effector molecules, and/or participate 
in an alternative pathway, remains unclear. More research is 
necessary to better understand the mechanism of the ATR 
pathway at fragile sites and its effect on cancer development. 
PERSPECTIVES 
  Herein we present a model for fragile site instability in 
the formation of cancer-specific chromosomal rearrange-
ments in the context of RET/PTC1 rearrangement formation, 



































Fig. (1). Model of fragile site instability in the formation of cancer-specific chromosomal rearrangements. RET and CCDC6 genes, 
located on chromosome 10 within the fragile sites FRA10G and FRA10C respectively, are closer than expected during interphase in normal 
thyroid cells. In the normal thyroid gland, RET is not expressed in follicular cells, while CCDC6 is constitutively expressed. Under conditions 
of replication stress, replicative DNA polymerases , , and  become uncoupled from the helicase/topoisomerase complex, resulting in long 
stretches on single-stranded DNA susceptible to the formation of stable secondary structures. These structures can cause replication fork stall-
ing, triggering the ATR-dependent DNA damage checkpoint pathway. Fragile sites may also be susceptible to spontaneous fork reversal or 
polymerase skipping at regions of secondary structure. For repair of stalled forks, ATR binds to the fragile DNA either directly or through 
complexes, and activates a downstream signaling cascade with other proteins, including CHK1, BRCA1, FANCD2, WRN, Claspin, HUS1, 
ATM, and SMC1. If the ATR pathway properly responds, the replication fork will be repaired and DNA replication will resume normally. A 
loss, deficiency, or defect in ATR pathway proteins could lead to checkpoint failure and/or replication fork collapse resulting in DNA break-
age at RET and CCDC6. DNA breakage at these sites can lead to the formation of RET/PTC1 translocations, the expression of oncogenic 
RET protein, and the development of papillary thyroid carcinoma. 334    Current Genomics, 2010, Vol. 11, No. 5  Dillon et al. 
results in the formation of translocations like those observed 
in patient tumors (Fig. 1). RET and CCDC6 genes, located 
within the fragile sites FRA10G and FRA10C respectively, 
are in close proximity during interphase in normal thyroid 
cells [72, 73], thus promoting the formation of rearrange-
ment. Under conditions of replication stress, such as those 
environmental and dietary agents known to induce fragile 
sites, replicative DNA polymerases become uncoupled from 
the helicase/topoisomerase complex, resulting in long 
stretches on single-stranded DNA. Regions that maintain 
single-strandedness, such as the OIZ, may promote the for-
mation of stable secondary structures due to the intrinsic 
features of fragile DNA. These structures can cause signifi-
cant difficulties during replication, resulting in a stalled rep-
lication fork. The ATR-dependent DNA damage checkpoint 
pathway, which responds to stalled or collapsed replication 
forks, is then triggered. In some cases, a stalled replication 
fork may spontaneously regress during synthesis of fragile 
DNA, generating a Holliday junction-like intermediate 
which could lead to breakage through cleavage by resolvase 
enzymes [113], or polymerase bypass might occur at regions 
of structure formation resulting in chromosome deletions. 
For repair of stalled forks, ATR, the main sensor of the 
pathway, binds to the fragile DNA either directly or through 
complexes and activates a downstream signaling cascade 
through phosphorylation of various targets, including central 
regulator CHK1. Other components of the ATR pathway, 
including BRCA1, FANCD2, WRN, Claspin, HUS1, and 
SMC1, are crucial for fragile site maintenance, although 
their direct role remains unclear. If the ATR pathway prop-
erly responds, the replication fork will be repaired and DNA 
replication will resume normally. However, a loss, defi-
ciency, or defect in ATR pathway proteins could lead to 
checkpoint failure and/or replication fork collapse resulting 
in DNA breakage, the initiating event of translocation forma-
tion. Therefore, breakage at RET and CCDC6 can lead to the 
formation of RET/PTC1 translocations in sporadic tumors 
through a fragile site-mediated mechanism, resulting in the 
development of sporadic papillary thyroid carcinomas. 
  Several studies have shown a strong correlation between 
the location of fragile sites and sites of breakage in a few 
cancer-specific chromosomal aberrations. We showed that 
over half of breakpoints in all reported recurrent cancer-
specific chromosomal translocations are within known frag-
ile sites, but that this is an underestimation, since only simple 
translocations were investigated [65]. There may be other 
fragile sites in the genome as yet unidentified. A recent re-
port by Mrasek et al. found 61 fragile sites previously not 
observed and 52 previously not verified, all of which are 
APH-inducible [14]. Intriguingly, all classes of rare and 
common fragile sites were induced by APH. These results 
suggest that fragile sites may have an even greater role in 
carcinogenesis than previously thought. Since certain dietary 
and environmental factors can induce or enhance breakage of 
various APH-induced common fragile sites, it is conceivable 
that the newly identified sites are also targeted by these 
agents, thus increasing the risk of cancer development. 
Futhermore, these results strongly suggest a role for fragile 
sites in the development of sporadic cancer. Future studies 
are needed to elucidate the mechanism of fragile site instabil-
ity in the formation of cancer-specific chromosomal aberra-
tions and the contribution of dietary and environmental fac-
tors in this process.  
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